Vera Therapeutics | 10-Q: Quarterly report
Vera Therapeutics Is Maintained at Strong Buy by Raymond James
Vera Therapeutics Is Maintained at Strong Buy by Raymond James
Raymond James: Maintaining the Vera Therapeutics (VERA.US) rating, adjusted from strong buy to strong buy rating, and adjusted the target price from $57.00 to $68.00.
Raymond James: Maintaining the Vera Therapeutics (VERA.US) rating, adjusted from strong buy to strong buy rating, and adjusted the target price from $57.00 to $68.00.
Raymond James Maintains Strong Buy on Vera Therapeutics, Raises Price Target to $68
Raymond James analyst Steven Seedhouse maintains Vera Therapeutics with a Strong Buy and raises the price target from $57 to $68.
Vera Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 66.34% Raymond James $57 → $68 Maintains Strong Buy 04/05/2024 36.99% Guggenheim → $56 Reiterat
Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating
Vera Therapeutics (VERA) has an average rating of buy and price targets ranging from $25 to $107, according to analysts polled by Capital IQ. Price: 41.55, Change: -0.78, Percent Change: -1.84
UPDATE: Vera Therapeutics Q1 EPS $(0.56) Up From $(0.80) YoY
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(0.56) per share. This is a 30 percent increase over losses of $(0.80) per share from the same period last year.
Press Release: Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results -- Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard
Vera Therapeutics 1Q Loss/Shr 56c >VERA
Vera Therapeutics 1Q Loss/Shr 56c >VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 1, 2024, the Compensation Committee of Vera's Board of Directors granted inducem
Vertex Doesn't Seem To Have Engaged With Other Players Before Alpine Deal -- Market Talk
1454 ET - Vertex Pharmaceuticals seems not to have explored alternatives before its deal for kidney-disease treatment developer Alpine. Evercore ISI analysts Liisa Bayko and Jingming Chen say in a res
Could This Stock Be the Next Biotech Buyout?
Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ...
Vera Therapeutics(VERA.US) Officer Sells US$228.56K in Common Stock
$Vera Therapeutics(VERA.US)$ Officer Young Joseph R sold 5,714 shares of common stock on Apr 10, 2024 at an average price of $40 for a total value of $228.56K.Source: Announcement What is statement of
Vertex Pharmaceuticals to Buy Alpine Immune Sciences in $4.9B Deal
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
On Wednesday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) agreed to acquire Alpine Immune Sciences Inc (NASDAQ:ALPN) for $65 per share or approximately $4.9 billion in cash. Evercore notes the d
Vertex Pharma Upgraded at Evercore on Alpine Immune Deal
Vera Therapeutics Shares Are Trading Higher in Sympathy With Alpine Immune, Which Entered an Agreement to Be Acquired by Vertex.
Vera Therapeutics Shares Are Trading Higher in Sympathy With Alpine Immune, Which Entered an Agreement to Be Acquired by Vertex.
Analysts' Top Healthcare Picks: Emergent Biosolutions (EBS), Vera Therapeutics (VERA)
Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM), Avidity Biosciences (RNA) and Vera Therapeutics (VERA)
No Data